Genetic determinants of bone mass

Current Opinion in Rheumatology

Volumn 16, Issue 4, 2004, Pages 450-456

  Baldock, P A ^a   Eisman, John A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; LEPTIN; LIPOPROTEIN RECEPTOR; LIPOXYGENASE; NEUROPEPTIDE Y; WNT PROTEIN;

BONE MASS; ETHNOLOGY; FRACTURE; GENE MUTATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENETIC LINKAGE; GENETIC VARIABILITY; HEREDITY; HUMAN; HYPOTHALAMUS; LIPID METABOLISM; MEDICAL EXAMINATION; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; BONE DENSITY; HUMANS; LDL-RECEPTOR RELATED PROTEINS; LEPTIN; MICE; MICE, KNOCKOUT; MUTATION; NEUROPEPTIDE Y; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, LDL;

EID: 3042624677     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moo.0000127828.34643.b4     Document Type: Review

References (73)

1. Gong Y, Slee RB, Fukai N, et al.: Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
2. Little RD, Carulli JP, Del Mastro RG, et al.: A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70:11-19.
3. Boyden LM, Mao J, Belsky J, et al.: High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-1521.
4. Van Hul E, Gram J, Bollerslev J, et al.: Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. J Bone Miner Res 2002, 17:1111-1117.
5. Kato M, Patel MS, Levasseur R, et al.: Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularisation in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002, 157:303-314.
6. Van Wesenbeeck L, Cleiren E, Gram J, et al.: Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Gen 2003, 72:763-771. Highlights the presence of this novel mutation in a variety of existing high bone mass conditions and the increasing evidence for the importance of this locus for skeletal health.
7. Fujino T, Asaba H, Kang MJ, et al.: Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A 2003, 100:229-234.
8. Balemans W, Foernzler D, Parsons C, et al.: Lack of association between the SOST gene and bone mineral density in perimenopausal women: analysis of five polymorphisms. Bone 2003, 31:515-319. Frequency of SNPs in the gene implicated in sclerosteosis did not differ between perimenopausal white women with high (top 16%, n = 326) vs low (bottom 16%, n = 293) BMD in a case-control study.
9. Bilezikian JP: The medical management of primary hyperparathyroidism. Ann Intern Med 1982, 96:198-202.
10. Ducy P, Amling M, Takeda S, et al.: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-207.
11. Baldock PA, Sainsbury A, Couzens M, et al.: Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002, 109:915-921.
12. Sainsbury A, Baldock PA, Schwarzer C, et al.: Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol 2003, 23:5225-5233. Novel genetic models highlight the magnitude of the skeletal response to Y receptor deletion; also includes influence on metabolic parameters.
13. Takeda S, Elefteriou F, Levasseur R, et al.: Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
14. Majeska RJ, Minkowitz B, Bastian W, et al.: Effects of beta-adrenergic blockade in an osteoblast-like cell line. J Orthop Res 1992, 10:379-384.
15. Imai S, Matsusue Y: Neuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P-, and tyrosine hydroxylase-containing nerves and the bone. Micros Res Tech 2002, 58:61-69.
16. Hoff AO, Catala-Lehnen P, Thomas PM, et al.: Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 2002, 110:1849-1857.
17. Zaidi M, Moonga BS, Abe E: Calcitonin and bone formation: a knockout full of surprises. J Clin Invest 2002, 110:1769-1771.
18. Beamer WG, Donahue LR, Rosen CJ, et al.: Genetic variability in adult bone density among inbred strains of mice. Bone 1996, 18:397-403.
19. Beamer WG, Shultz KL, Donahue LR, et al.: Quantitative trait loci for femoral and lumbar vertebral bone mineral density in C57BL/6J and C3H/HeJ inbred strains of mice. J Bone Miner Res 2001, 16:1195-1206.
20. Masinde GL, Li X, Gu W, et al.: Quantitative trait loci for bone density in mice: the genes determining total skeletal density and femur density show little overlap in F2 mice. Calcif Tissue Int 2002, 71:421-428.
21. Turner CH, Hsieh YF, Muller R, et al.: Genetic regulation of cortical and trabecular bone strength and microstructure in inbred strains of mice. J Bone Miner Res 2000, 15:1126-1131.
22. Turner CH, Hsieh YF, Muller R, et al.: Variation in bone biomechanical properties, microstructure, and density in BXH recombinant inbred mice. J Bone Miner Res 2001, 16:206-213.
23. Koller DL, White KE, Liu G, et al.: Linkage of structure at the proximal femur to chromosomes 3, 7, 8, and 19. J Bone Miner Res 2003, 18:1057-1065.
24. Gardiner EM, Baldock PA, Thomas GP, et al.: Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J 2000, 14:1908-1916.
25. Klein RF, Allard J, Avnur Z, et al.: Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004, 303:229-232. Comprehensive study bringing together genetic and genomic techniques along with pharmacologic interventions as evidence for the actions of Alox 15 in bone.
26. Klein RF, Shea M, Gunness ME, et al.: Phenotypic characterization of mice bred for high and low peak bone mass. J Bone Miner Res 2001, 16:63-71.
27. Lecka-Czernik B, Moerman EJ, Grant DF, et al.: Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143:2376-2384.
28. Ogawa S, Urano T, Hosoi T, et al.: Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 1999, 260:122-126.
29. Liu YZ, Liu YJ, Recker RR, et al.: Molecular studies of identification of genes for osteoporosis: the 2002 update. J Endocrinol 2003, 177:147-196. An excellent systematic collation of association and linkage studies in humans and QTL loci in animal studies.
30. Gennari L, Becherini L, Falchetti A, et al.: Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. J Steroid Biochem Mol Biol 2002, 81:1-24.
31. McGuigan FE, Murray L, Gallagher A, et al.: Genetic and environmental determinants of peak bone mass in young men and women. J Bone Miner Res 2002, 17:1273-1279.
32. Karasik D, Myers RH, Hannan MT, et al.: Mapping of quantitative ultrasound of the calcaneus bone to chromosome 1 by genome-wide linkage analysis. Osteoporos Int 2002, 13:796-802.
33. Carn G, Koller DL, Peacock M, et al.: Sibling pair linkage and association studies between peak bone mineral density and the gene locus for the osteoclast-specific subunit (OC116) of the vacuolar proton pump on chromosome 11p12-13. J Clin Endocrinol Metab 2002, 87:3819-3824.
34. Styrkarsdottir U, Cazier J-B, Kong A, et al.: Linkage of osteoporosis to chromosome 20p12 and association with BMP2. PLoS Biol 2003, 1:1-10. In a linkage study of 207 Icelandic families, comprising 1323 individuals, linkage was found to chromosome 20P12. This was localized to the BMP2 gene in association studies involving 2281 "affected" individuals and 3286 matched controls from Iceland and Denmark.
35. Rivadeneira F, Houwing-Duistermaat JJ, Vaessen N, et al.: Association between an insulin-like growth factor I gene promoter polymorphism and bone mineral density in the elderly: the Rotterdam Study. J Clin Endocrinol Metab 2003, 88:3878-3884.
36. Kim JG, Roh KR, Lee JY: The relationship among serum insulin-like growth factor-I, insulin-like growth factor-I gene polymorphism, and bone mineral density in postmenopausal women in Korea. Am J Obstet Gynecol 2002, 186:345-350.
37. Yamada Y, Ando F, Niino N, et al.: Association of polymorphisms of paraoxonase 1 and 2 genes, alone or in combination, with bone mineral density in community-dwelling Japanese. J Hum Genet 2003a, 48:469-475. Nonconservative coding region polymorphisms in gene related to lipid peroxidation associated with reduced bone mass in more than 1000 postmenopausal Japanese women but not in premenopausal women or men.
38. Abrahamsen B, Madsen JS, Tofteng CL, et al.: A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study. J Bone Miner Res 2003, 18:723-729.
39. Omasu F, Ezura Y, Kajita M, et al.: Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. J Hum Genet 2003, 48:342-345. Genetic variation in the reversion-induced LIM gene within the cytokine cluster on chromosomes (5q31.1) in 370 adult Japanese women was associated with radial BMD.
40. Yamada Y, Ando F, Niino N, et al.: Association of polymorphisms of interleukin-6, osteocalcin, and vitamin D receptor genes, alone or in combination, with bone mineral density in community-dwelling Japanese women and men. J Clin Endocrinol Metab 2003b, 88:3372-3378.
41. Chung HW, Seo JS, Hur SE, et al.: Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women. J Hum Genet 2003, 48:243-248.
42. Garnero P, Borel O, Sornay-Rendu E, et al.: Association between a functional interleukin-6 gene polymorphism and peak bone mineral density and postmenopausal bone loss in women: the OFELY study. Bone 2002, 31:43-50.
43. Ferrari SL, Ahn-Luong L, Garnero P, et al.: Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003, 88:255-259. In 495 postmenopausal women, two allelic loci in the IL-6 promoter were associated additively with serum C-reactive protein and urinary markers of bone turnover and weakly with bone density.
44. Chen HY, Chen WC, Wu MC, et al.: Interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphism in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis. Maturitas 2003, 30:49-54. A polymorphism in the IL-1β, but not IL-1 receptor antagonist, gene was associated with lower BMD and increased fracture risk. Wide confidence intervals reflected the uncommonness of the risk genotype (4.7% of 172 women).
45. Wennberg P, Nordstrom P, Lorentzon R, et al.: TNF-alpha gene polymorphism and plasma TNF-alpha levels are related to lumbar spine bone area in healthy female Caucasian adolescents. Eur J Endocrinol 2002, 146:629-634.
46. Ota N, Nakajima T, Ezura Y, et al.: Association of a single nucleotide variant in the human tumour necrosis factor alpha promoter region with decreased bone mineral density. Ann Hum Biol 2002, 29:550-558.
47. Albagha OM, Tasker PN, McGuigan FE, et al.: Linkage disequilibrium between polymorphisms in the human TNFRSF1B gene and their association with bone mass in perimenopausal women. Hum Mol Genet 2003, 11:2289-2295. 3′UTR SNPs of the TNF receptor 1B, examined in 1240 perimenopausal UK women, were associated with 1.25% of variance of hip BMD in a small subset (7%).
48. Willing MC, Torner JC, Burns TL, et al.: Gene polymorphisms, bone mineral density and bone mineral content in young children: the Iowa Bone Development Study. Osteoporos Int 2003, 14:650-658. Genotypes in eight candidate genes (COL1A1 and COL1A2, osteocalcin, osteonectin, osteopontin, VDR, ER, and AR) were examined in relation to bone density in 428 healthy non-Hispanic white children (228 girls and 200 boys aged 4.5-6.5 years). BMD/BMC measures were most consistently associated with COL1A2 and osteocalcin genotypes, less consistently with osteonectin, osteopontin, and VDR polymorphisms and not at all with COL1A1 (Rsal and Sp1), VDR (Bsml), or ER polymorphisms (Pvull, Xbal, TA). There were also gene-by-gene interaction effects for ER with VDR and osteocalcin.
49. Remes T, Vaisanen SB, Mahonen A, et al.: Aerobic exercise and bone mineral density in middle-aged Finnish men: a controlled randomized trial with reference to androgen receptor, aromatase, and estrogen receptor alpha gene polymorphisms. Bone 2003, 32:412-420. In middle-aged Finnish men, ERa genotype was associated with BMD but not response to exercise. Neither AR CAG nor aromatase TTTA repeat polymorphisms were associated with BMD or its response to exercise.
50. Strandberg S, Nordstrom P, Lorentzon R, et al.: Vitamin D receptor start codon polymorphism (Fokl) is related to bone mineral density in healthy adolescent boys. J Bone Miner Metab 2003, 21:109-113. In this longitudinal study of 88 adolescent boys, a VDR polymorphism was associated with spine, but not hip, bone mineral content, size, and BMD and not BMD change over 2 years.
51. Chen HY, Chen WC, Hsu CD, et al.: Relation of vitamin D receptor Fokl start codon polymorphism to bone mineral density and occurrence of osteoporosis in postmenopausal women in Taiwan. Acta Obstet Gynecol Scand 2002, 81:93-98.
52. Chen HY, Chen WC, Wu MC, et al.: Androgen receptor (AR) gene microsatellite polymorphism in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis. Eur J Obstet Gynecol Reprod Biol 2003, 107:52-56. In a small study in postmenopausal Chinese women, an AR gene polymorphism subgroup (64 of 168) was associated with lower BMD and increase fracture risk.
53. Tsai FJ, Chen WC, Chen HY, et al.: The ALUI calcitonin receptor gene polymorphism (TT) is associated with low bone mineral density and susceptibility to osteoporosis in postmenopausal women. Gynecol Obstet Invest 2003, 55:82-87. In 167 postmenopausal Taiwanese women, a relatively uncommon polymorphism in the CT receptor gene was associated with lower spine and hip BMD. In this small study there were only 2.4% or four women in the high-risk group.
54. Garcia-Giralt N, Nogues X, Enjuanes A: Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density. J Bone Miner Res 2002, 17:384-393.
55. Van Pottelbergh I, Goemaere S, De Bacquer D, et al.: Vitamin D receptor gene allelic variants, bone density, and bone turnover in community-dwelling men. Bone 2002, 31:631-637.
56. Koh JM, Kim DJ, Hong JS, et al.: Estrogen receptor alpha gene polymorphisms Pvu II and Xba I influence association between leptin receptor gene polymorphism (Gln223Arg) and bone mineral density in young men. Eur J Endocrinol 2002, 147:777-783.
57. Braga V, Sangalli A, Malerba G, et al.: Relationship among VDR (Bsml and Fokl), COLIA1, and CTR polymorphisms with bone mass, bone turnover markers, and sex hormones in men. Calcif Tissue Int 2002, 70:457-462.
58. Katsumata K, Nishizawa K, Unno A, et al.: Association of gene polymorphisms and bone density in Japanese girls. J Bone Miner Metab 2002, 20:164-169.
59. Ioannidis JP, Stavrou I, Trikalinos TA, et al.: Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis. J Bone Miner Res 2002, 17:2048-2060.
60. Gong G, Haynatzki G: Association between bone mineral density and candidate genes in different ethnic populations and its implications. Calcif Tissue Int 2003, 72:113-123. Ethnic differences in polymorphisms at 25 candidate loci were analyzed from studies of white and Asian groups. Most polymorphisms associated with BMD appear to be very old and common in major ethnic populations, implying they are very close to and likely within the candidate genes.
61. Lei SF, Deng FY, Liu XH, et al.: Polymorphisms of four bone mineral density candidate genes in Chinese populations and comparison with other populations of different ethnicity. J Bone Miner Metab 2003, 21:34-42. Allele frequencies differed widely between Chinese and previously reported white subjects in polymorphisms of the collagen type IAI, IL-6, glucocorticoid receptor, and transforming growth factor β(1) genes.
62. Palomba S, Numis FG, Mossetti G, et al.: Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with Bsml vitamin D receptor genotypes. Clin Endocrinol 2003, 58:3653-3657.
63. Palomba S, Numis FG, Mossetti G, et al.: Raloxifene administration in postmenopausal women with osteoporosis: effect of different Bsml vitamin D receptor genotypes. Hum Reprod 2003, 18:192-198.
64. Giannini S, D'Angelo A, Nobile M, et al.: The effects of vitamin D receptor polymorphism on secondary hyperparathyroidism and bone density after renal transplantation. J Bone Miner Res 2002, 17:1768-1773.
65. Blanchet C, Giguere Y, Prud'homme D, et al.: Association of physical activity and bone: influence of vitamin D receptor genotype. Med Sci Sports Exerc 2002, 34:24-31.
66. Qreshi AM, Herd RJ, Blake GM, et al.: COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif Tissue Int 2002, 70:158-163.
67. Yoneda K, Tanji Y, Ikeda N, et al.: Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett 2002, 186:223-230.
68. Masi L, Becherini L, Gennari L, et al.: Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J Clin Endocrinol Metab 2001, 86:2263-2269.
69. Zmuda JM, Cauley JA, Danielson ME, et al.: Vitamin D receptor and aromatase gene interaction and bone mass in older African-American women. Metabolism 2003, 52:521-523.
70. Salmen T, Heikkinen AM, Mahonen A, et al.: Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women. Ann Med 2003, 35:282-288.
71. Salmen T, Heikkinen AM, Mahonen A, et al.: Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial. J Bone Miner Res 2003, 18:319-324. In a 5-year randomized trial of hormone replacement therapy in 331 early postmenopausal Finnish women, an AR gene polymorphism was not associated with baseline bone density or response to treatment.
72. Sapir-Koren R, Livshits G, Kobyliansky E: Genetic effects of estrogen receptor alpha and collagen IA1 genes on the relationships of parathyroid hormone and 25 hydroxyvitamin D with bone mineral density in Caucasian women. Metabolism 2003, 52:1129-1135. A combination of ER and Col1A1 alleles, associated with lower bone density, were also associated with higher levels of PTH and bone turnover in this small study of 122 elderly women.
73. Zhang YY, Long JR, Liu PY, et al.: Estrogen receptor alpha and vitamin D receptor gene polymorphisms and bone mineral density: association study of healthy pre- and postmenopausal Chinese women. Biochem Biophys Res Commun 2003, 308:777-783. A significant association was observed between ER and VDR polymorphisms in 388 premenopausal and 261 postmenopausal Chinese women with evidence of gene-gene interaction in the postmenopausal women.